CD274 and non-small cell lung carcinoma: In patients with platinum-treated PD-L1+ NSCLC, avelumab did not significantly prolong OS as compared with docetaxel in the primary analysis [137], a 2-year follow-up data of JAVELIN LUNG 200 showed that OS rates were doubled with avelumab in subgroups with higher PD-L1 expression (greater than or equal to 50% and greater than or equal to 80%) [138].